Sonoma Pharmaceuticals Inc. Common Stock
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as Loyon for the management of skin scaling. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
SNOA Overview
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$1.1400 |
Previous Close Volume |
18700 |
Latest News
- Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices 05 Dec 2024 08:35:35
- Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States 21 Nov 2024 16:35:41
- Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel 11 Nov 2024 16:34:40
- Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results 07 Nov 2024 08:50:06
- Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf 31 Oct 2024 16:04:36
- Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada 22 Oct 2024 09:05:21
- Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences 21 Oct 2024 16:05:51
- Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule 19 Sep 2024 08:34:41
- Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution 17 Sep 2024 09:04:28
-
Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line
11 Sep 2024 08:34:53
https://ir.sonomapharma.com/press-releases/detail/416/sonoma-pharmaceuticals-and-emc-pharma-announce
- Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock 28 Aug 2024 06:34:39
- Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff 26 Aug 2024 08:35:21
- Sonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States 21 Aug 2024 09:04:20
- Sonoma Pharmaceuticals Reports First Fiscal Quarter 2025 Financial Results 08 Aug 2024 16:36:33
- Sonoma Pharmaceuticals Celebrates 20 Years of Selling Wound Care Products in Europe and Announces New Distributor in Ukraine 09 Jul 2024 07:36:35
- Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results 17 Jun 2024 17:06:41
- Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores 09 May 2024 07:51:49
-
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
09 Apr 2024 07:52:05
https://ir.sonomapharma.com/press-releases/detail/408/sonoma-pharmaceuticals-announces-expansion-of
- Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections 04 Apr 2024 07:37:09
- Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences 28 Mar 2024 16:22:48
- Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals 27 Mar 2024 07:52:28
- Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results 08 Feb 2024 16:35:57
- Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use 23 Jan 2024 07:37:43